Skip to content
Insurance, Medical Health Aged Care

GMHBA appoints Michael Sammells to Board of Directors

GMHBA 2 mins read

MEDIA RELEASE

 

10 October 2023

GMHBA appoints Michael Sammells to Board of Directors

GMHBA Ltd is pleased to announce the appointment of Mr Michael Sammells to its Board of Directors. Mr Sammells has over 35 years of professional experience, with significant involvement in senior executive financial and commercial roles.

As a former Chief Financial Officer at both Medibank Private and Healthscope he developed an extensive understanding of the private health insurance industry and private hospital operations. He also brings a valuable perspective to the Board having held operational roles with expertise in finance, accounting, treasury, investor relations, capital developments, mergers and acquisitions and IPOs.

Mr Sammells is a non-executive director of AMP, Chair of Sigma Healthcare and has served on numerous private boards.

GMHBA Chair, Claire Higgins, said the Board is very pleased to have Mr Sammells join the Board, where his insights and expertise will be greatly valued.

“As GMHBA continues to put member outcomes in the centre of our work, we are very pleased to have Michael join our board.  He has a deep understanding of the private health insurance sector and the hospital and health sector.  This, together with his style and the breadth of his experience is sure to be an asset,” she said.

Mr Sammells said he was looking forward to joining GMHBA as the organisation works to improve access to quality health care through our new apps and new extra products and continue to attract more members to the business.

“I’m very pleased to be joining a purposeful, member-focused organisation with a strong Board and look forward to making a positive contribution to GMHBA and the communities in which it operates,” he said.

Mr Sammells will begin his term as a Director on the GMHBA Board on 16 October 2023.

The appointment follows the retirement of board member Brian Benger at our Annual Meeting of Fund Members last month, who came to the end of his tenure having joined in 2011.

Brian was a valued and respected board member, bringing his significant experience in financial services to the Board, and providing oversight of the growth and management of the fund’s investment portfolio. Notably, Brian also played an instrumental role representing GMHBA as co-investor with Quintessential Equity in the 60 Moorabool Street redevelopment as a director on the joint development Company.


About us:

About us:

GMHBA is an Australian not for profit health insurance and care company. We have served the community since 1934, and with almost 90 years’ experience, we have become Australia’s leading regionally based private health insurer. Through our personalised approach and exceptional customer service, we put the health and wellbeing of our members and communities first. Our approach is guided by our philosophy, Healthier Together and decisions are made with our members first and foremost in mind.


Contact details:

For all GMHBA media enquiries please contact Head of Corporate Communications Meg Rayner on 0458 418 823 or megrayner@gmhba.com.au

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.